scispace - formally typeset
Open AccessJournal ArticleDOI

Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.

TLDR
In this paper, the authors investigated the regulation of HDAC2 on the IFNγ-induced PD-L1 expression in triple-negative breast cancer (TNBC) cells, and they found that HDAC 2 promoted PD-l1 induction by upregulating the phosphorylation of JAK1, JAK2, and STAT1.
Abstract
The PD-L1 overexpression is an important event of immune escape and metastasis in triple-negative breast cancer (TNBC), but the molecular mechanism remains to be determined. Interferon gamma (IFNγ) represents a major driving force behind PD-L1 expression in tumor microenvironment, and histone deacetylase 2 (HDAC2) is required for IFN signaling. Here, we investigated the regulation of HDAC2 on the IFNγ-induced PD-L1 expression in TNBC cells. We found the HDAC2 and PD-L1 expression in TNBC was significantly higher than that in non-TNBC, and HDAC2 was positively correlated with PD-L1 expression. HDAC2 promoted PD-L1 induction by upregulating the phosphorylation of JAK1, JAK2, and STAT1, as well as the translocation of STAT1 to the nucleus and the recruitment of STAT1 to the PD-L1 promoter. Meanwhile, HDAC2 was recruited to the PD-L1 promoter by STAT1, and HDAC2 knockout compromised IFNγ-induced upregulation of H3K27, H3K9 acetylation, and the BRD4 recruitment in PD-L1 promoter. In addition, significant inhibition of proliferation, colony formation, migration, and cell cycle of TNBC cells were observed following knockout of HDAC2 in vitro. Furthermore, HDAC2 knockout reduced IFNγ-induced PD-L1 expression, lymphocyte infiltration, and retarded tumor growth and metastasis in the breast cancer mouse models. This study may provide evidence that HDAC2 promotes IFNγ-induced PD-L1 expression, suggesting a way for enhanced antitumor immunity when targeting the HDAC2 in TNBC.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Nanomaterial-assisted CRISPR gene-engineering – A hallmark for triple-negative breast cancer therapeutics advancement

TL;DR: In this article , a review of all possible genetic mechanisms of triple negative breast cancer occurrence, available treatments and gene therapies for TNBC, and overview of the delivery system and utilization of CRISPR-nano complex in TNBC.
Journal ArticleDOI

Clinical Significance of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer

TL;DR: Higher HDAC-2 expression was related to lobular histological type of cancer, grade III, and stage III BC, and other factors correlating with worse survival were histological types other than ductal or lobular, and the stage of the disease.
Journal ArticleDOI

Histone deacetylase 2 regulates STAT1-dependent upregulation of atypical chemokine receptor 3 to induce M2 macrophage migration and immune escape in hepatocellular carcinoma.

TL;DR: In this paper , the effects of ACKR3 and its regulatory molecules on the chemotactic migration of tumor-associated macrophages (TAMs) in hepatocellular carcinoma (HCC) were investigated.
Journal ArticleDOI

Epigenetic modifications: Critical participants of the PD-L1 regulatory mechanism in solid tumors (Review)

TL;DR: A rational combination of epigenetic regulation and PD-1/PD-L1 axis blockade may improve the prognosis of patients with solid tumors and explore novel therapeutic strategies to improve immunosuppression response rates and overcome drug resistance.
Journal ArticleDOI

Gold-Promoting-Satellite to Boost Photothermal Conversion Efficiency of Cu2-Se for Triple Negative Breast Cancer Targeting Therapy

TL;DR: In this paper , a novel gold-promoting satellite Cu2-xSe (GPS-CS) nanoparticle was developed by simple in situ reduction, which exhibited higher photothermal conversion efficiency and less toxicity than the bare copper chalcogenide nanocrystal.
References
More filters
Journal ArticleDOI

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

TL;DR: Atezolizumab plus nab‐paclitaxel prolonged progression‐free survival among patients with metastatic triple‐negative breast cancer in both the intention‐to‐treat population and the PD‐L1–positive subgroup.
Journal ArticleDOI

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

TL;DR: Induction of the B7-H1/PD-1 pathway may represent an adaptive immune resistance mechanism exerted by tumor cells in response to endogenous antitumor activity and may explain how melanomas escape immune destruction despite endogenous antitUMor immune responses.
Journal ArticleDOI

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

TL;DR: Evaluating several potential therapeutic response markers including the PD-L1 and PD-1 expression pattern, genetic mutations within cancer cells and neoantigens, cancer epigenetics and effector T cell landscape, and microbiota and the mechanisms of action of these markers clarify.
Journal ArticleDOI

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

TL;DR: This Review will focus the discussion on three basic principles that define this unique therapeutic approach and highlight how anti-PD therapy is distinct from other immunotherapeutic approaches, namely tumor site immune modulation, targeting tumor-induced immune defects, and repairing ongoing (rather than generating de novo) tumor immunity.
Journal ArticleDOI

PD-L1 Expression in Triple-Negative Breast Cancer

TL;DR: Using tissue microarrays containing 105 triple-negative breast cancer specimens, Mittendorf and colleagues show that 20% of the TNBC specimens express PD-L1, half have lost PTEN, and inhibitors of PI3K pathway decrease PD- l1 expression, providing a rationale for therapeutic targeting of PD- L1 for TNBC.
Related Papers (5)